Sponsored Links
| Erbitux Increased Overall Survival By 5.1 Months In Those With MCRC That Has Spread Beyond The Liver |
 |
 |
 |
| Medical News - Colorectal Cancer | |||
|
In alignment with this year's American Society of Clinical Oncology (ASCO) Annual Meeting theme, 'Patients, Pathways, Progress', Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced the presentation of a retrospective analysis of the CRYSTAL trial demonstrating that Erbitux® (cetuximab) significantly improves outcomes in metastatic colorectal cancer (... Read more: Colorectal Cancer News From Medical News Today
|